Chemotherapy for metastatic melanoma - Time for a change?

被引：184

作者：

Gogas, Helen J.

Kirkwood, John M.

Sondak, Vernon K.

机构：

[1] Univ Athens, Dept Med 1, Athens 11510, Greece

[2] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA

[3] Univ Pittsburgh, Inst Canc, Melanoma Program, Pittsburgh, PA 15260 USA

[4] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33620 USA

来源：

CANCER | 2007年 / 109卷 / 03期

关键词：

biochemotherapy; complete durable response; systemic chemotherapy; metastatic melanoma; PHASE-II TRIAL; DISSEMINATED MALIGNANT-MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; RANDOMIZED-TRIAL; COMBINATION CHEMOTHERAPY; EUROPEAN ORGANIZATION; ANTITUMOR-ACTIVITY; DACARBAZINE; CISPLATIN; INTERLEUKIN-2;

D O I：

10.1002/cncr.22427

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Melanoma is a neoplasm with a rising incidence. Early-stage melanoma is curable, but advanced, metastatic melanoma almost uniformly is fatal, and patients with such advanced disease have a short median survival. Systemic therapy remains unsatisfactory, inducing complete durable responses in a small minority of patients. For the current review, the authors focused on the current role of cytotoxic chemotherapy in the treatment of metastatic melanoma and the future prospects for improvements for multiagent chemotherapy and chemotherapy combined with immunomodulatory and/or molecularly targeted agents. They discuss roles of single-agent chemotherapy, combination chemotherapy, combinations of chemotherapy with immunomodulatory or hormone agents, biochemotherapy. and combination chemotherapy with targeted therapies.

引用

页码：455 / 464

页数：10

共 86 条

[1] DOCETAXEL (TAXOTERE) IN ADVANCED MALIGNANT-MELANOMA - A PHASE-II STUDY OF THE EORTC EARLY CLINICAL-TRIALS GROUP [J].

AAMDAL, S ;

WOLFF, I ;

KAPLAN, S ;

PARIDAENS, R ;

KERGER, J ;

SCHACHTER, J ;

WANDERS, J ;

FRANKLIN, HR ;

VERWEIJ, J .

EUROPEAN JOURNAL OF CANCER, 1994, 30A (08) :1061-1064

[2]

AHMAD T, 2004, J CLIN ONCOL S, V22, pA14

[3]

Allen IE, 1998, CANC THER, V1, P168

[4]

AMARAVADI RK, 2006, J CLIN ONCOL S, V24, pS18

[5]

[Anonymous], P AM SOC CLIN ONCOL

[6] MULTIINSTITUTIONAL PHASE-II TRIAL OF INTENSIVE COMBINATION CHEMOIMMUNOTHERAPY FOR METASTATIC MELANOMA [J].

ATKINS, MB ;

OBOYLE, KR ;

SOSMAN, JA ;

WEISS, GR ;

MARGOLIN, KA ;

ERNEST, ML ;

KAPPLER, K ;

MIER, JW ;

SPARANO, JA ;

FISHER, RI ;

ECKARDT, JR ;

PEREIRA, C ;

ARONSON, FR .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1553-1560

[7]

ATKINS MB, 2005, J CLIN ONCOL S, V23, pS16

[8]

Atkins Michael B., 1997, Current Opinion in Oncology, V9, P205

[9] Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].

Avril, MF ;

Aamdal, S ;

Grob, JJ ;

Hauschild, A ;

Mohr, P ;

Bonerandi, JJ ;

Weichenthal, M ;

Neuber, K ;

Bieber, T ;

Gilde, K ;

Porta, VG ;

Fra, J ;

Bonneterre, J ;

Saïag, P ;

Kamanabrou, D ;

Pehamberger, H ;

Sufliarsky, J ;

Larriba, JLG ;

Scherrer, A ;

Menu, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125

[10] COMBINATION CHEMOTHERAPY OF DACARBAZINE AND FOTEMUSTINE IN DISSEMINATED MALIGNANT-MELANOMA - EXPERIENCE OF THE FRENCH STUDY-GROUP [J].

AVRIL, MF ;

BONNETERRE, J ;

DELAUNAY, M ;

GROSSHANS, E ;

FUMOLEAU, P ;

ISRAEL, L ;

BUGAT, R ;

NAMER, M ;

CUPISSOL, D ;

KERBRAT, P ;

MONTCUQUET, P ;

ARCAUTE, V ;

BIZZARI, JP .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (02) :81-84

← 1 2 3 4 5 6 7 8 9 →